Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
For patients receiving HLA-matched sibling donor transplantation, antithymocyte globulin can reduce the incidence of acute graft-vs-host-disease.